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The global, regional, and national burden of cirrhosis by cause 
in 195 countries and territories, 1990–2017: a systematic 
analysis for the Global Burden of Disease Study 2017 
GBD 2017 Cirrhosis Collaborators*
Summary
Background Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major 
cause of morbidity and mortality globally, although the burden and underlying causes difer across locations and 
demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.
Methods We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. 
We modelled prevalence of total, compensated, and decompensated cirrhosis on the basis of hospital and claims data. 
Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost due to premature death and years 
lived with disability. Estimates are presented as numbers and age-standardised or age-speciic rates per 
100 000 population, with 95% uncertainty intervals (UIs). All estimates are presented for ive causes of cirrhosis: 
hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), and other causes. We 
compared mortality, prevalence, and DALY estimates with those expected according to the Socio-demographic Index 
(SDI) as a proxy for the development status of regions and countries.
Findings In 2017, cirrhosis caused more than 1·32 million (95% UI 1·27–1·45) deaths (440 000 [416 000–518 000; 33·3%] 
in females and 883 000 [838 000–967 000; 66·7%] in males) globally, compared with less than 899 000 (829 000–948 000) 
deaths in 1990. Deaths due to cirrhosis constituted 2·4% (2·3–2·6) of total deaths globally in 2017 compared with 1·9% 
(1·8–2·0) in 1990. Despite an increase in the number of deaths, the age-standardised death rate decreased from 
21·0 (19·2–22·3) per 100 000 population in 1990 to 16·5 (15·8–18·1) per 100 000 population in 2017. Sub-Saharan Africa 
had the highest age-standardised death rate among GBD super-regions for all years of the study period 
(32·2 [25·8–38·6] deaths per 100 000 population in 2017), and the high-income super-region had the lowest 
(10·1 [9·8–10·5] deaths per 100 000 population in 2017). The age-standardised death rate decreased or remained constant 
from 1990 to 2017 in all GBD regions except eastern Europe and central Asia, where the age-standardised death rate 
increased, primarily due to increases in alcohol-related liver disease prevalence. At the national level, the age-standardised 
death rate of cirrhosis was lowest in Singapore in 2017 (3·7 [3·3–4·0] per 100 000 in 2017) and highest in Egypt in all 
years since 1990 (103·3 [64·4–133·4] per 100 000 in 2017). There were 10·6 million (10·3–10·9) prevalent cases of 
decompensated cirrhosis and 112 million (107–119) prevalent cases of compensated cirrhosis globally in 2017. There was 
a signiicant increase in age-standardised prevalence rate of decompensated cirrhosis between 1990 and 2017. Cirrhosis 
caused by NASH had a steady age-standardised death rate throughout the study period, whereas the other four causes 
showed declines in age-standardised death rate. The age-standardised prevalence of compensated and decompensated 
cirrhosis due to NASH increased more than for any other cause of cirrhosis (by 33·2% for compensated cirrhosis and 
54·8% for decompensated cirrhosis) over the study period. From 1990 to 2017, the number of prevalent cases more than 
doubled for compensated cirrhosis due to NASH and more than tripled for decompensated cirrhosis due to NASH. In 
2017, age-standardised death and DALY rates were lower among countries and territories with higher SDI.
Interpretation Cirrhosis imposes a substantial health burden on many countries and this burden has increased at the 
global level since 1990, partly due to population growth and ageing. Although the age-standardised death and DALY 
rates of cirrhosis decreased from 1990 to 2017, numbers of deaths and DALYs and the proportion of all global deaths 
due to cirrhosis increased. Despite the availability of efective interventions for the prevention and treatment of 
hepatitis B and C, they were still the main causes of cirrhosis burden worldwide, particularly in low-income countries. 
The impact of hepatitis B and C is expected to be attenuated and overtaken by that of NASH in the near future. Cost-
efective interventions are required to continue the prevention and treatment of viral hepatitis, and to achieve early 
diagnosis and prevention of cirrhosis due to alcohol-related liver disease and NASH.
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license.
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Introduction 
Cirrhosis is the leading cause of liver-related death 
globally.1 It is the end stage of progressive liver ibrosis, in 
which the hepatic architecture is distorted.2 In the initial 
stages, cirrhosis is compensated. Most patients are 
asymptomatic at this stage, and cirrhosis is usually 
discovered incidentally during medical encounters for 
other reasons. Thus, reports on the prevalence of 
compensated cirrhosis are almost always underestimated. 
Decompensation in patients with compensated cirrhosis 
is usually deined as the irst occurrence of ascites, 
oesophageal variceal bleeding, hepatic encephalopathy, 
and, in some individuals, increased bilirubin concen-
tration.3,4 Because of the nature of decompensation, these 
patients are rapidly brought to medical attention, and 
thus reports on the prevalence of decompensated 
cirrhosis are probably much more accurate than those of 
compensated cirrhosis.3 Once decompensation occurs, 
the mortality and morbidity resulting from cirrhosis 
increase sharply, and depending on the cause of 
decompensation, the 1-year case-fatality rate can be as 
high as 80%.5,6 Almost all of the mortality and morbidity 
resulting from cirrhosis is caused by the decompensated 
type. Such patients need frequent medical attention and 
an increasing amount of medication over the disease 
course. Quality of life is afected and frequent 
hospitalisations (admissions and stays) are required.7 
As the disease progresses, hospital stays become more 
frequent and more prolonged. Finally, patients either die 
or receive a liver transplant, which is a high-burden 
option for patients, health-care systems, and health 
inancing and governance.7
Compensated cirrhosis is more benign. Patients often 
have a life expectancy similar to that of healthy adults if 
cirrhosis remains compensated.5 However, identifying 
these patients is important because if they are not treated 
appropriately, they are at risk of progressing to 
decompensated cirrhosis.3
Cirrhosis is generally considered to be irreversible at 
later stages, although reversal has been documented in 
many individuals with compensated cirrhosis after 
treating the underlying cause.8–10 The most common 
causes of cirrhosis are chronic hepatitis B and C, alcohol-
related liver disease, and non-alcoholic steatohepatitis 
(NASH).7 Patients with decompensated cirrhosis are 
susceptible to complications and a reduction in life 
expectancy.11
Despite being a global health challenge, estimates of 
cirrhosis mortality and morbidity are not widely available, 
especially at national levels, because of data sparsity in 
many regions where cirrhosis is fatal, particularly in 
Africa.12 Accurate mortality data are also scarce, because 
oicial death records under-report cirrhosis as a cause of 
death.13 The burden of cirrhosis difers considerably across 
locations, sexes, races and ethnicities, and socioeconomic 
strata, and the burden has also varied substantially over 
time. Moreover, the incidence and prevalence of cirrhosis 
are not well established, even in population-based studies. 
Studies are further limited by referral bias; the structure of 
the population under study (inpatient vs outpatient); 
absence of standardised deinitions; and diversity in 
methods of assessment, including self-reporting, laboratory 
tests and non-invasive biomarkers, imaging, liver biopsies, 
and death certiicates.12
Research in context
Evidence before this study
In 1994, an analysis of official death certification data derived 
from the WHO database was conducted, and reports were 
released on deaths due to cirrhosis from 1955 to 1990 in high-
income countries. More recently, a 2014 report on findings 
from the Global Burden of Disease Study (GBD) 2010 reported 
the mortality of cirrhosis and other chronic liver diseases in 
187 countries from 1980 to 2010. Both estimates showed 
increasing numbers and decreasing rates across almost all 
countries. Other local studies have also shown the 
contributions of vaccination and lifestyle modification to 
reductions in death rates, incidence, and prevalence of cirrhosis.
Added value of this study
In this study we present the results of the latest iteration of GBD 
(2017), regarding cirrhosis and other chronic liver diseases 
(hereafter referred to as cirrhosis). Compared with GBD 2016, 
we had access to more data points, we used novel and more 
robust methods, we made separate estimates for 
decompensated and compensated cirrhosis, and we 
differentiated non-alcoholic steatohepatitis as the fifth cause of 
cirrhosis along with hepatitis B and C, alcohol-related liver 
disease, and the broad category of other causes. Our study 
provides a valuable insight into  the shifting burden of cirrhosis 
due to different causes. Although hepatitis B caused the 
greatest proportion of cirrhosis deaths in 2017, our findings 
suggest that non-alcoholic steatohepatitis might become the 
leading cause of cirrhosis in the near future.
Implications of all the available evidence
The number of deaths and prevalent cases of both 
decompensated and compensated cirrhosis are increasing, 
despite a decrease in age-standardised death rates. The 
contribution of different causes to mortality and morbidity is 
expected to change as a result of available prevention and 
treatment modalities. Because of variation in the 
contribution of the five causes of cirrhosis assessed in this 
study and varying amounts and trends of burden across 
nations, policies should be targeted at national and even 
subnational levels accordingly. We intend for our findings 
to be used by policy makers and the public to address the 
increasing burden of chronic liver diseases.
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Data by cause are also inaccurate and diverse. 
Clariication of the underlying cause and stage of 
cirrhosis is challenging, even in high-income countries.14 
It is generally well-recognised that the contribution of 
underlying causes is variable across locations and has 
changed over time. With the availability of methods for 
controlling hepatitis B and curing hepatitis C,15 along 
with rising prevalence of metabolic syndrome and 
obesity as a plausible underlying cause, the proportion of 
cirrhosis mortality and morbidity caused by NASH is 
expected to increase in the near future.16,17
Previous studies have investigated the burden of 
cirrhosis at the global level. In 1994, La Vecchia and 
colleagues18 analysed oicial death certiication data from 
1955 to 1990 derived from the WHO database to produce 
estimates covering 38 high-income countries. In 2014, 
Mokdad and colleagues19 reported the results of the 
2010 iteration of the Global Burden of Disease Study 
(GBD) on mortality due to cirrhosis by four causes in 
187 countries from 1980 to 2010. Both studies reported 
increasing numbers of deaths and decreasing age-
standardised mortality rates in most countries. However, 
updated estimates on mortality and morbidity caused by 
cirrhosis and the prevalence of decompensated and 
compensated types by cause were not available, to our 
knowledge, before this study. Using data from GBD 2017, 
this study provides estimates of the prevalence, mortality, 
and disability-adjusted life-years (DALYs) of cirrhosis and 
other chronic liver diseases by cause, sex, and age at 
global, regional, and national levels across 195 countries 
and territories from 1990 to 2017.
Methods
Overview
This study is part of GBD 2017,1,20–22 which was a systematic 
efort to estimate the levels and trends of burden caused 
by 359 diseases and injuries by sex, age, year (1990–2017), 
and location, including seven super-regions, 21 regions, 
and 195 countries and territories. We modelled the 
mortality and prevalence of cirrhosis and other chronic 
liver diseases, hereafter collectively referred to as 
cirrhosis. We report numbers and age-standardised and 
age-speciic rates for mortality, prevalence, and DALYs, 
which are the sum of years of life lost (YLLs) due to 
premature death and years lived with disability 
(YLDs).1,20–22 This study is compliant with the Guidelines 
for Accurate and Transparent Health Estimates Reporting.
We considered diagnoses coded as B18 and K70–77 in 
the International Classiication of Diseases 10th revision 
(ICD-10) to be compensated and decompensated cirrhosis. 
ICD-10 codes B18.0–18.2 were mapped to chronic viral 
hepatitis B and C in the GBD cause list, B18.8 and 18.9 to 
other causes, K70 to alcohol-related liver disease, K75.81 to 
NASH, and the rest of the codes to the category of other 
causes, which included but was not limited to autoimmune 
hepatitis (K75.4). The detailed list of ICD-10 codes mapped 
to the GBD cause list is reported in the appendix (p 4). 
The causes grouped in the “other chronic liver diseases” 
category mainly included auto immune hepatitis, toxic 
liver diseases, other inlam matory liver diseases, chronic 
hepatitis not speciied, and other diseases of the liver 
(K76). ICD-10 codes for acute hepatitis were not included 
in this study. Non-alcoholic fatty liver disease was 
considered to be a separate entity from compensated and 
decompensated cirrhosis, and codes for diabetes were also 
excluded. Finally, deaths caused by hepatocellular 
carcinoma were excluded because: ICD-10 codes deine 
hepatocellular carcinoma as a cause irrespective of liver 
cirrhosis; hepatocellular carcinoma can be distinguished 
from cirrhosis in countries with adequate data; and 
implications on natural history and management of the 
two causes are not similar.
Existing evidence shows that ICD-10 coding is valid for 
deining overall cirrhosis and chronic liver diseases in 
most of the data sources used to assemble the cause-of-
death database but does not have the required accuracy 
for reporting cirrhosis by the ive causes estimated in the 
current study.23,24 The models that we used to split the 
parent cirrhosis mortality and morbidity into the ive 
causes are described below.
Mortality estimates
Details of the methods used to estimate mortality 
have been published previously.1,20–22 We modelled decom-
pensated cirrhosis mortality due to the ive causes deined 
by the aforementioned ICD-10 codes using all available 
data in the cause-of-death database. We obtained data 
from vital registrations, vital registration samples, and 
verbal autopsies. Vital registrations are systems that 
governments use to record the vital events of their 
residents, including causes of death. Vital registration 
samples are nationally representative cluster samples in 
countries where vital registration has low coverage or is 
unavailable. Verbal autopsy is a method by which causes 
of death and cause-speciic mortality fractions in 
populations without a complete vital registration system 
are determined. To record data through verbal autopsy, 
trained interviewers collect information about the 
symptoms, signs, and demographic characteristics of a 
recently deceased person from an individual familiar with 
the deceased person. The majority of the cause-of-death 
data are vital registration data obtained from the WHO 
Mortality Database, which consists of data submitted to 
WHO by individual countries. Vital registration data are 
also obtained from country-speciic mortality databases 
operated by oicial oices. We collected 19 329 data points 
from vital registrations, 793 data points from vital 
registration samples, and 1263 points from verbal 
autopsies. To address problems of zero counts in vital 
registration and verbal autopsy for a given age group in a 
given year, we used a Bayesian noise-reduction algorithm.1 
We used Cause of Death Ensemble models (CODEm) to 
estimate liver cirrhosis mortality with uncertainty by age, 
sex, country or territory, and year. CODEm is the See Online for appendix
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framework used to model most cause-speciic death rates 
in GBD.1 First, all available data were identiied and 
gathered. Second, a diverse set of plausible models were 
developed to capture well-documented associations in the 
estimates. The use of a wide range of individual models 
to create an ensemble predictive model has been shown 
to outperform techniques that use only a single model, 
both in cause-of-death estimation and in more general 
prediction applications.25 Third, the out-of-sample 
predictive validity was assessed for all individual models, 
which were then ranked for use in the ensemble 
modelling stage. Finally, diferently weighted com-
binations of individual models were evaluated to select 
the ensemble model with the highest out-of-sample 
predictive validity.
The methods we used for propagating uncertainty are 
the same as those used in previous GBD iterations. At 
each step of the computation process, we took 1000 draws 
and then computed inal estimates using the mean 
estimate across the draws. 95% uncertainty intervals 
(UIs) were calculated as the 25th and 975th ranked values 
across all 1000 draws.
In GBD 2017, NASH was included as a ifth cause of 
cirrhosis for the irst time. Cirrhosis caused by NASH 
was previously nested within the category of other 
cirrhosis. As discussed previously, we were able to use 
the cause-of-death database only for estimating overall 
cirrhosis and not its ive causes. Instead, we used 
DisMod-MR 2.1 to split the parent cirrhosis mortality 
estimates and used liver cancer aetiological proportion 
models as covariates. These covariates included alcohol 
consumption (L per capita), HBsAg seroprevalence, 
hepatitis C (anti-hepatitis C virus antibody) sero-
prevalence, and obesity. Proportions from the ive 
aetiological models were then rescaled to sum to one at 
the draw level and used to split the parent cirrhosis 
mortality estimates.
Morbidity estimates 
We modelled total cirrhosis prevalence and decom-
pensated and compensated cirrhosis on the basis of 
hospital data and claims data, using diferent deinitions 
for each model. Total cirrhosis prevalence was deined 
as any diagnosis of cirrhosis. The distinction between 
decompensated and compensated cirrhosis was based 
on the diagnosis made upon hospital admission. If 
cirrhosis was the primary diagnosis upon hospital 
admission, we considered the case to be decompensated. 
If cirrhosis was diagnosed in outpatient settings or was 
detected among patients admitted to the hospital for 
other causes, we considered the case to be compensated.
A systematic review of the literature was done to 
identify studies on the proportion of cirrhosis cases 
attributable to alcohol-related liver disease, hepatitis B, 
hepatitis C, NASH, and other causes. We re-extracted all 
literature within our databases on cirrhosis cause 
proportions for cirrhosis due to NASH. We searched the 
peer-reviewed literature via PubMed and solicited sources 
from GBD 2017 collaborators. The inclusion criteria 
stipulated that the publication year was 1980 or later; the 
sample was representative of patients with decompensated 
cirrhosis (eg, studies of patients with both hepatocellular 
carcinoma and hepatitis were excluded); suicient 
information was provided on study method and sample 
characteristics to assess the quality of the study; and 
hepatitis B and C were conirmed via HBsAg in the case 
of hepatitis B, and anti-hepatitis C virus antibody in the 
case of hepatitis C. The number of site-years of data by 
cause is provided in the appendix (p 4).
We modelled cirrhosis prevalence using hospital data 
and cause-speciic mortality rates, assuming no 
remission.20 Similar to the mortality estimates, we 
developed aetiological proportion models using DisMod-
MR 2.1 and used the results of these models to split the 
parent total cirrhosis prevalence estimates. We adopted 
the aetiological proportion model from liver cancer. We 
irst developed ive single-parameter DisMod models, 
each to estimate the proportion of liver cancer due to a 
given cause (ie, alcohol, hepatitis B, hepatitis C, NASH, 
and other). Estimates from these liver cancer models 
were then used as covariates in the ive corresponding 
cirrhosis aetiological models. Proportions from the 
ive aetiological models were then rescaled to sum to one 
at the draw level and used to split the parent cirrhosis 
estimates. We multiplied these fractions by prevalence 
separately for decom pensated and compensated 
cirrhosis by age, sex, year, and location, and estimated 
the prevalence due to cirrhosis by each cause. Upon 
calculation of cause fractions, we encountered some 
reports on cirrhosis due to more than one cause. In 
these cases, we redistributed the numbers proportionally 
on the number of cases diagnosed with only one cause.
To calculate YLDs, prevalence was multiplied by a 
disability weight, which represents the magnitude of the 
health loss associated with disease. Disability weights are 
measured on a scale from 0 to 1, where 0 is a state of full 
health and 1 is death. Compensated cirrhosis has a 
disability weight of 0 because of its asymptomatic nature. 
Decompensated cirrhosis from any cause has a disability 
weight of 0·178 (95% UI 0·122–0·250).20
We used the Socio-demographic Index (SDI) to 
determine the relationship between the development level 
of a region or country and cirrhosis mortality, prevalence, 
and DALYs. In GBD 2017, the SDI was revised to better 
relect the development status of each country. The SDI 
ranges from 0 (worst) to 1 (best) and is a composite 
measure of the total fertility rate in women under the age 
of 25 years, mean education for individuals aged 15 years 
and older, and lag-distributed income per capita.
All estimates are reported in terms of counts, rates 
per 100 000 population, and percentages. Population 
estimates independently produced by GBD 2017 were used 
as references for calculating age-standardised death rates 
and age-standardised prevalence.26 95% UIs, including all 
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sources of uncertainty arising from measurement error, 
systematic biases, and modelling, are reported for all 
estimates. All estimates of mortality, prevalence, DALYs, 
YLDs, and YLLs are reported by sex and age, and across 
location and time period studied (1990–2017).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. The corresponding authors had full 
access to the data in the study and had inal responsibility 
for the decision to submit for publication.
Results
Globally, cirrhosis caused more than 1·32 million 
(95% UI 1·27–1·45) deaths in 2017, with 440 000 deaths 
(416 000–518 000; 33·3%) in females and 883 000 
(838 000–967 000; 66·7%) in males, compared with less 
than 899 000 (829 000–948 000) deaths for both sexes in 
1990 (igure 1; appendix p 5). These deaths constituted 
2·4% (2·3–2·6) of all deaths globally in 2017 compared 
with 1·9% (1·8–2·0) in 1990. The age-standardised 
death rate at the global level decreased from 21·0 
(19·2–22·3) per 100 000 population in 1990 to 16·5 
(15·8–18·1) per 100 000 population in 2017 (igure 1). 
The age-standardised death rate was consistently lowest 
in the high-income super-region (10·1 [9·8–10·5] per 
100 000 in 2017) and highest in the sub-Saharan Africa 
super-region (32·2 [25·8–38·6] per 100 000 in 2017) in 
all years from 1990 to 2017 (appendix p 237). The pattern 
of age-standardised death rates between 1990 and 2017 
was similar in males and females, although the rates 
were consistently higher in males than females in all 
super-regions (estimates available through the GBD 
online results tool and data visualisation tool) and all 
years from 1990 to 2017 (igure 1).
Cirrhosis led to nearly 41·4 million (95% UI 39·6–45·1) 
DALYs in 2017, which was an increase from just over 
30·5 million (28·6–32·2) in 1990. The age-standardised 
rate of DALYs decreased from 656·4 (612·8–689·2) per 
100 000 population in 1990 to 510·7 (487·6–557·1) per 
100 000 population in 2017 (appendix p 15). In 2017, 
cirrhosis caused 28·8 million DALYs (27·3–31·4) in 
males and 12·6 million DALYs (11·9–14·7) in females, 
compared with 20·6 million DALYs (18·7–21·8) in males 
and 9·9 million (9·1–11·1) DALYs in females in 1990. The 
age-standardised DALY rates in 2017 were 719·3 
(683·0–784·9) per 100 000 population in males and 307·6 
(288·5–359.6) per 100 000 in females, which was a 
substantial decrease from 1990 (903·1 [820·1–956·1] per 
100 000 in males and 415·5 [382·5–457·1] per 100 000 in 
females in 1990; estimates available through the GBD 
online results tool).
The number of prevalent cases of decompensated 
cirrhosis globally increased from more than 
5·20 million (95% UI 5·08–5·32) in 1990 to over 
10·6 million (10·3–10·9) in 2017 (appendix p 23), of 
which 6·42 million (6·23–6·60; 60·3%) prevalent cases 
were in males and 4·23 million (4·10–4·35; 39·7%) 
were in females (data not shown). The age-standardised 
prevalence of decompensated cirrhosis increased 
from 110·6 (108·0–113·0) per 100 000 population in 
1990 to 132·5 (128·6–136·2) per 100 000 population in 
2017 (appendix p 23). In males, the age-standardised 
prevalence in 2017 was 162·7 (157·9–167·3) per 100 000, 
with a 21·1% (19·7–22·4) increase from 1990 to 2017. In 
females, the age-standardised prevalence in 2017 was 
103·5 (100·6–106·3) per 100 000, with an 18·1% 
Figure 1: Counts and age-standardised rates of cirrhosis death at the global level by sex, 1990–2017
Error bars indicate 95% UIs for number of deaths. Shading indicates 95% UIs for age-standardised death rates. UI=uncertainty interval.
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(16·9–19·2) increase from 1990 to 2017 (data not 
shown).
The number of global prevalent cases of compensated 
cirrhosis increased from 65·9 million (95% UI 63·4–68·7) 
in 1990 to just over 112 million (107–119) in 2017 
(appendix p 32), of which 66·1 million (62·7–69·7; 58·8%) 
prevalent cases were in males and 46·3 million (43·8–48·8; 
41·2%) were in females (data not shown). The age-
standardised prevalence of compensated cirrhosis 
increased from 1354·5 (1300·6–1411·7) per 100 000 in 
1990 to 1395·0 (1323·5–1470·5) in 2017 (appendix p 32).
The age-standardised prevalence of compensated 
cirrhosis in males was 1605·4 (95% UI 1543·3–1671·2) 
per 100 000 in 1990 and 1651·4 (1567·5–1742·8) per 
100 000 in 2017. The age-standardised prevalence of 
compensated cirrhosis in females was 1103·3 
(1055·6–1152·4) per 100 000 in 1990 and 1142·4 
(1079·9–1204·0) per 100 000 in 2017 (data not shown). 
Figure 2: Age-standardised rates for cirrhosis by region and sex, 2017
(A) Age-standardised death rate. (B) Age-standardised prevalence rate of compensated and decompensated cirrhosis. Error bars indicate 95% uncertainty intervals 
for age-standardised rates.
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The percentage change in age-standardised prevalence 
rate of compensated cirrhosis from 1990 to 2017 was 
2·9% (0·4–5·2) in males and 3·5% (1·3–5·6) in females 
(data not shown).
At the regional level, central Asia had the highest age-
standardised death rate due to cirrhosis in 2017 for males, 
females, and both sexes combined (39·0 [95% UI 
36·2–41·5] per 100 000 for both sexes combined; igure 2A), 
with deaths largely driven by alcohol-related liver disease 
(36·6% of all cirrhosis deaths). Western, eastern, and 
central sub-Saharan Africa had the next highest age-
standardised death rates for both sexes combined in 2017, 
with rates of 35·8 (23·9–49·9) per 100 000 population in 
western Africa, 34·8 (26·4–42·2) per 100 000 population in 
eastern Africa, and 34·3 (25·9–45·2) per 100 000 population 
in central sub-Saharan Africa (igure 2A). In central and 
eastern sub-Saharan Africa in 2017, the most common 
cause of death due to cirrhosis was hepatitis C (32·4% and 
28·9%, respectively), followed by hepatitis B (31·2% and 
25·9%, respectively; appendix p 41). However, in western 
sub-Saharan Africa, the most common cause of death due 
to cirrhosis was hepatitis B (48·9%) in all countries in the 
region, whereas the proportion of deaths from hepatitis C 
was much lower in this region (7·8%) than in the other 
sub-Saharan African regions (appendix p 41).
Southeast Asia ranked ifth in terms of age-standardised 
death rate from cirrhosis across regions in 2017 (29·5 
[95% UI 27·7–31·9] per 100 000) but had low age-
standardised prevalence rates of compensated and 
decompensated cirrhosis (igure 2A, B); both deaths and 
prevalent cases were mainly caused by hepatitis B and C 
(appendix pp 41, 48, 55).
Eastern Europe ranked sixth in terms of age-
standardised death rate due to cirrhosis in 2017 
(25·9 [95% UI 25·0–26·7] per 100 000), and, as in central 
Asia, deaths were primarily caused by alcohol-related 
liver disease (igure 2A; appendix pp 5, 41). These two 
regions were the only ones in which age-standardised 
death rates signiicantly increased over the study period: 
by 137·0% (129·5–146·2) in eastern Europe and by 
50·5% (38·6–59·9) in central Asia (appendix p 5). The 
age-standardised death rate increased by more than 100% 
in all but one country (Moldova) in eastern Europe 
(appendix p 5). Eastern Europe had a high and increasing 
age-standardised prevalence of both decompensated and 
compensated cirrhosis from 1990 to 2017; prevalent cases 
were predominantly caused by alcohol-related liver 
disease (igure 2B; appendix pp 48, 55).
The age-standardised death rate was lowest in 
Australasia (5·4 [95% UI 4·9–6·0] per 100 000 population), 
east Asia (8·3 [7·6–10·7] per 100 000 population), and 
high-income Asia Paciic (8·6 [7·9–9·1] per 
100 000 population; igure 2A). Australasia was among 
the regions with the lowest age-standardised prevalence 
of both compensated and decompensated cirrhosis 
(igure 2B). Deaths due to cirrhosis and prevalent cases 
of compensated and decompensated cirrhosis in this 
region were primarily caused by hepatitis C 
(appendix pp 48, 55). East Asia had the second-lowest 
age-standardised death rate, but it had a relatively high 
age-standardised prevalence rate for compensated and 
decompensated cirrhosis combined (igure 2A, B). 
Deaths due to cirrhosis and prevalent cases of 
compensated and decompensated cirrhosis in this region 
were driven primarily by hepatitis B (appendix pp 41, 48, 55).
High-income Asia Paciic had the third lowest age-
standardised death rate in 2017 and all countries in this 
region experienced a steep decline over the study period, 
particularly South Korea (igure 2A; appendix p 5). 
However, this region had the highest age-standardised 
prevalence for both compensated cirrhosis (2455·0 
[95% UI 2344·9–2575·8] per 100 000) and decompensated 
cirrhosis (267·4 [259·8–275·1] per 100 000) in 2017 
(igure 2B). The high age-standardised prevalence in this 
region was primarily driven by high numbers of prevalent 
cases in Japan, where the highest proportions of 
compensated and decompensated cirrhosis were due to 
hepatitis C (appendix pp 23, 32, 48, 55).
Western Europe, southern sub-Saharan Africa, and 
high-income North America had the fourth to sixth 
lowest age-standardised death rates of cirrhosis in 2017 
(igure 2A; appendix p 5). In western Europe, deaths 
were primarily caused by alcohol-related liver disease 
(41·7%), whereas in southern sub-Saharan Africa and 
high-income North America, deaths were primarily 
caused by hepatitis C (33·9% and 34·7%, respectively; 
appendix p 41). Western Europe and southern sub-
Saharan Africa had modest age-standardised prevalence 
rates of both compensated and decompensated cirrhosis, 
whereas high-income North America had the lowest age-
standardised prevalence of compensated cirrhosis of all 
regions; prevalent cases in this region were mainly 
caused by hepatitis C (igure 2B; appendix pp 48, 55).
South Asia and Oceania had modest age-standardised 
death rates but were among the regions with the lowest 
age-standardised prevalence of compensated and 
decompensated cirrhosis (igure 2A, B). Deaths due to 
cirrhosis and prevalent cases of compensated and 
decompensated cirrhosis were primarily caused by 
hepatitis B in these regions (appendix p 41).
Central Latin America was among the regions with the 
highest age-standardised prevalence of both compensated 
(2272·3 [95% UI 2167·0–2383·4] per 100 000) and 
decompensated (206·6 [200·4–212·6] per 100 000) 
cirrhosis (igure 2B; appendix pp 23, 32), although age-
standardised death rates were modest in this region. 
Other regions in Latin America had modest age-
standardised death rates and age-standardised prevalence 
rates of both types of cirrhosis. Cirrhosis deaths in Latin 
American regions were primarily driven by alcohol-
related liver disease, except for tropical Latin America 
(38·1% in Andean Latin America, 36·6% in central Latin 
America, 34·8% in the Caribbean, and 34·6% in 
southern Latin America; appendix p 41). Cirrhosis deaths 
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in tropical Latin America were mainly attributable to 
hepatitis C. In every Latin American region, the cause of 
the highest proportion of cirrhosis deaths was also the 
cause of the highest proportion of compensated and 
decompensated cirrhosis prevalent cases (appendix 
pp 48, 55).
Finally, north Africa and the Middle East had modest 
age-standardised death and prevalence rates from 
cirrhosis, with the largest proportion of deaths due to 
cirrhosis and prevalent cases of compensated and 
decompensated cirrhosis driven by hepatitis B and C.
Speciic country and territory data can be found in the 
appendix (pp 5–14 for age-standardised death rates; 
pp 15–22 for DALYs, pp 23–40 for prevalence, and 
pp 41–68 for cause). Egypt had the highest age-
standardised death rate of cirrhosis in all years from 
1990 to 2017, despite a 22·4% (95% UI 1·5–42·1) decrease 
from 1990 (133·1 [76·4–150·8] per 100 000) to 2017 (103·3 
[64·4–133·4] per 100 000). The second highest rate was in 
Rwanda in 1990 (88·1 [71·9–104·8] per 100 000) and in 
Cambodia in 2017 (79·4 [67·4–96·1] per 100 000; 
igure 3A; appendix p 5). In 2017, 41·5% of deaths due to 
cirrhosis in Egypt were caused by hepatitis B and 34·4% 
were caused by hepatitis C (appendix p 41).
The lowest age-standardised death rate of cirrhosis in 
2017 was in Singapore (3·7 [95% UI 3·3–4·0] per 
100 000 population). The largest increase in age-
standardised death rate from 1990 to 2017 was in 
Lithuania (176·7% [154·1–203·2]; appendix p 5). The 
eight countries with the largest increases in age-
standardised death rate from cirrhosis over the study 
period (in order: Lithuania, Ukraine, Belarus, Russia, 
Kazakhstan, Estonia, Latvia, and Armenia) were all in 
eastern Europe or central Asia (appendix p 5). In all of 
these countries, the largest proportion of deaths in 2017 
was caused by alcohol-related liver disease (appendix p 41).
Among the ten countries with the highest age-
standardised prevalence of decompensated cirrhosis in 
2017, eight were from central and eastern Europe (in order: 
Slovakia [349·6, 95% UI 338·4–361·2] per 100 000, 
Moldova, Romania, Poland, Ukraine, Lithuania, Albania, 
and Hungary), in addition to Japan (third-highest; 279·8 
[272·0–287·8] per 100 000) and South Korea (eighth-
highest; 245·9 [237·8–253·9] per 100 000; igure 3B; 
appendix p 23). The Philippines had the lowest age-
standardised prevalence of decompensated cirrhosis in 
2017 (41·8 [40·2–43·4 per 100 000 population]), with the 
largest proportion of prevalent cases due to hepatitis B.
Figure 3: Age-standardised death rate for cirrhosis in 2017 (A), age-standardised prevalence for decompensated cirrhosis (B), and age-standardised prevalence for compensated cirrhosis (C), 
2017
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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Despite decreasing age-standardised prevalence of 
compensated cirrhosis since 1990, South Korea and 
Japan were among the ten countries with the highest 
rates in 2017 (igure 3C; appendix p 32). The three 
countries or territories with the highest age-standardised 
prevalence of compensated cirrhosis were Moldova, 
Taiwan (Province of China), and Slovakia.
Globally, in 2017, 31·5% of cirrhosis deaths in males 
were caused by hepatitis B, 25·5% were caused by 
hepatitis C, 27·3% were caused by alcohol-related liver 
disease, 7·7% were caused by NASH, and 8·0% resulted 
from other causes. In females, the proportions of 
cirrhosis deaths caused by hepatitis B (24·0%) and 
alcohol-related liver disease (20·6%) were lower than in 
males, the proportion caused by hepatitis C (26·7%) was 
similar to that in males, and the proportion caused by 
NASH (11·3%) and by other causes (17·3%) was higher 
than in males (igure 4).
Hepatitis B caused around 287 000 (95% UI 
252 000–318 000) deaths due to cirrhosis in 1990, which 
increased to almost 384 000 (349 000–442 000) in 2017. 
278 000 (252 000–321 000; 72·5%) of these deaths in 2017 
occurred in males, and 106 000 (94 000–130 000; 27·5%) 
occurred in females (appendix p 69). However, the age-
standardised death rate for both sexes combined 
decreased steadily from 6·7 (5·8–7·4) per 100 000 in 1990 
to 4·8 (4·3–5·5) per 100 000 in 2017 (igure 5; 
appendix p 69). The age-standardised death rate of 
cirrhosis due to hepatitis B was 7·2 (6·5–8·3) per 
100 000 in males and 2·5 (2·2–3·1) per 100 000 in females 
in 2017. Hepatitis B caused 36·7 million (95% UI 
34·1–39·5) prevalent cases of compensated cirrhosis and 
2·97 million (2·81–3·12) cases of decompensated 
cirrhosis in 2017. The age-standardised prevalence of 
decompensated cirrhosis caused by hepatitis B increased 
from 30·9 (95% UI 29·3–32·2) per 100 000 in 1990 to 
36·6 (34·7–38·4) per 100 000 in 2017 (appendix p 139). 
The age-standardised prevalence of compensated 
cirrhosis caused by hepatitis B did not change notably 
from 1990 (461·8 [435·8–491·2] per 100 000) to 2017 (451·9 
[95% UI 420·0–485·9] per 100 000; appendix p 184). 
Across regions, the proportion of deaths from cirrhosis 
due to hepatitis B was highest in western sub-Saharan 
Africa (48·9%) and lowest in high-income North America 
(5·7%; igure 4). The proportion of cirrhosis mortality 
that was caused by hepatitis B ranged from 5·7% in 
the USA to 54·8% in Chad (appendix pp 41).
Hepatitis C caused more than 225 000 (95% UI 
202 000–249 000) cirrhosis deaths in 1990, which 
increased to over 342 000 (313 000–381 000) in 2017. 
225 000 (203 000–251 000; 65·8%) of these deaths in 2017 
occurred in males, and 117 000 (107 000–135 000; 34·2%) 
occurred in females (appendix p 83). The age-standardised 
death rate decreased from 5·3 (4·8–5·9) per 100 000 in 
Figure 4: Proportion of deaths due to five causes of cirrhosis at global and regional levels by sex, 2017
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1990 to 4·2 (3·9–4·7) per 100 000 in 2017 (igure 5; 
appendix p 83). The age-standardised death rate due to 
hepatitis C was 5·8 (5·3–6·5) per 100 000 in males and 
2·8 (2·5–3·2) in females in 2017. Hepatitis C caused 
27·72 million (25·52–30·00) cases of compensated 
cirrhosis and 2·64 million (2·49–2·81) cases of decom-
pensated cirrhosis in 2017. The age-standardised 
prevalence of compensated cirrhosis caused by hepatitis C 
was 327·0 (303·9–349·7) per 100 000 in 1990 and 341·1 
(314·1–368·7) per 100 000 in 2017. The age-standardised 
prevalence of decompensated cirrhosis increased from 
27·2 (25·7–28·7) per 100 000 in 1990 to 32·5 (30·6–34·5) 
per 100 000 in 2017 (appendix pp 148, 193). Generally, the 
lowest proportions of cirrhosis mortality due to hepatitis 
C were observed in countries in western sub-Saharan 
Africa (7·8%) and the highest among countries in high-
income Asia-Paciic (41·3%; igure 4). The proportion of 
cirrhosis mortality that was caused by hepatitis C ranged 
from 7·1% in Niger to 55·7% in Tunisia (appendix p 41).
Alcohol-related liver disease caused just over 215 000 
(95% UI 195 000–235 000) cirrhosis deaths in 1990, which 
increased to just over 332 000 (303 000–373 000) deaths in 
2017. 241 000 (220 000–268 000; 72·6%) of these deaths in 
2017 occurred in males, and 91 000 (82 000–110 000; 27·4%) 
occurred in females. The age-standardised death rate 
decreased from 5·1 (4·6–5·5) per 100 000 in 1990 to 4·1 
(3·7–4·6) per 100 000 in 2017 (igure 5; appendix p 97). The 
age-standardised death rate due to alcohol-related liver 
disease was 6·2 (5·7–6·9) per 100 000 in males and 2·1 
(1·9–2·6) per 100 000 in females in 2017. Alcohol-related 
liver disease caused 23·6 million (21·9–25·5) cases of 
compensated cirrhosis and 2·46 million (2·32–2·61) cases 
of decompensated cirrhosis in 2017. The age-standardised 
prevalence of decompensated cirrhosis caused by alcohol-
related liver disease increased from 25·3 (23·9–26·7) per 
100 000 in 1990 to 30·0 (28·2–31·8) per 100 000 in 2017. 
The age-standardised prevalence of compensated cirrhosis 
caused by alcohol-related liver disease did not change 
notably from 1990 (290·0 [271·9–309·9] per 100 000) to 
2017 (288·1 [267·5–311·3] per 100 000; appendix pp 157, 
202). Among GBD regions, the highest proportions of 
cirrhosis deaths due to alcohol-related liver disease were 
in central Europe (44·0%), western Europe (41·7%), and 
Andean Latin America (38·1%; igure 4; appendix p 41). 
The proportion of cirrhosis deaths due to alcohol-related 
liver disease was lowest in north Africa and the Middle 
East (5·3%) and in Egypt speciically (4·8%), and highest 
in Belgium (53·5%; appendix p 41).
NASH caused almost 61 900 (95% UI 55 400–68 000) 
cirrhosis deaths in 1990, which increased to around 
118 000 (109 000–129 000) in 2017. 68 000 (62 000–75 000; 
57·6%) of these deaths in 2017 occurred in males, and 
50 000 (46 000–56 000; 42·4%) occurred in females. NASH 
was the only cause for which the age-standardised death 
rate did not decrease: the rate was 1·5 (1·3–1·6) per 
100 000 in 1990 and 1·5 (1·3–1·6) per 100 000 in 2017 
(igure 5; appendix p 111). The age-standardised death rate 
due to NASH was 1·8 (1·6–1·9) per 100 000 in males and 
1·2 (1·1–1·3) per 100 000 in females in 2017. NASH caused 
4·06 million (3·70–4·45) prevalent cases of compensated 
Figure 5: Number of deaths and age-standardised death rates at the global level by cause of cirrhosis, 1990–2017
Bars refer to number of deaths in each year. Lines refer to age-standardised death rate in each year. NASH=non-alcoholic steatohepatitis.
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Figure 6: Age patterns of 
deaths, DALYs, and 
prevalence of cirrhosis by 
sex, 2017
(A) Number of deaths and 
age-specific death rate per 
100 000 population. 
(B) Number of DALYs and age-
specific DALY rate per 
100 000 population. 
(C) Number of prevalent cases 
and age-specific prevalence 
rates per 100 000 population 
of decompensated and 
compensated cirrhosis. Error 
bars indicate 95% UIs for 
number of deaths, DALYs, and 
prevalent cases. Shading 
indicates 95% UIs for death 
rates, DALY rates, and 
prevalence rates. 
DALYs=disability-adjusted life-
years. UI=uncertainty interval. 
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cirrhosis in 1990 and 9·42 million (8·57–10·34) cases in 
2017 (more than doubling over the study period). NASH 
caused 325 000 (302 000–349 000) cases of decompensated 
cirrhosis in 1990 and 917 000 (850 000–986 000) cases in 
2017 (nearly tripling over the study period). The age-
standardised prevalence of compensated cirrhosis caused 
by NASH increased from 86·7 (79·0–94·6) per 100 000 in 
1990 to 115·5 (105–126·5) per 100 000 in 2017, a 33·2% 
increase. The age-standardised prevalence of decom-
pensated cirrhosis increased from 7·3 (6·8–7·8) per 
100 000 in 1990 to 11·3 (10·4–12·1) per 100 000 in 2017, a 
54·8% increase (appendix pp 166, 211). At the regional 
level, the proportion of deaths due to NASH was highest 
in Latin American regions, with the highest proportion in 
Tropical Latin America (22·6%) and Andean Latin 
America (22·2%). The lowest proportion was in high-
income Asia Paciic (4·7%; igure 4; appendix p 41). At the 
national level, the proportion of deaths due to NASH was 
highest in Ecuador (25·2%) and lowest in Singapore 
(2·7%).
Finally, other causes led to almost 110 000 (95% UI 
97 000–127 000) cirrhosis deaths in 1990, which increased 
to around 146 000 (131 000–165 000) in 2017. 70 000 
(62 000–80 000; 48·0%) of these deaths in 2017 occurred 
in males, and 76 000 (67 000–90 000) occurred in females 
(52·0%). The age-standardised death rate decreased from 
2·5 (2·2–2·8) per 100 000 in 1990 to 1·9 (1·7–2·1) per 
100 000 in 2017 (igure 5; appendix p 125). Other causes 
led to 15·0 million (13·6–16·2) cases of compensated 
cirrhosis and 1·65 million (1·55–1·76) cases of 
decompensated cirrhosis in 2017. The age-standardised 
prevalence of decompensated cirrhosis due to other 
causes was 20·0 (18·9–21·1) per 100 000 population  in 
1990 and 22·2 (20·9–23·5) per 100 000 in 2017. The age-
standardised prevalence of compensated cirrhosis due to 
other causes was 189·0 (173·0–204·6) per 100 000 
population in 1990 and 198·4 (180·1–215·4) per 100 000 
in 2017 (appendix pp 175, 220). At the regional level, the 
proportion of deaths due to other causes of cirrhosis was 
highest in high-income North America (20·6%) and 
lowest in east Asia (3·8%; igure 4; appendix p 41). At the 
national level, the highest proportion of deaths was in 
the UK (30·0%) and the lowest was in China (3·8%) and 
the United Arab Emirates (3·8%).
Patterns in burden by age were similar between males 
and females and across years from 1990 to 2017, although 
the numbers and rates were consistently higher in males 
than in females. The number of deaths peaked at 
60–64 years in both sexes combined in the years 
1990–2004 and 2011–17, and at 55–59 years for all other 
years (estimates available through the GBD results tool). 
In 2017, the number of deaths peaked in the 
60–64 year age group for males and the 65–69 year age 
group for females, whereas death rates increased steadily 
with age in every year of the study period (igure 6A). 
In 2017, the number of DALYs peaked at 50–54 years in 
males and at 55–59 years in females, whereas DALY rates 
peaked at 60–64 years in males and 70–74 years in females 
(igure 6B). The number of prevalent cases of compensated 
cirrhosis peaked at 45–49 years in females and 
40–44 years in males in 2017. The prevalence rate of 
compensated cirrhosis peaked at 45–49 years in males and 
at 50–54 years in females. The number of prevalent cases 
of decompensated cirrhosis peaked at 50–54 years in both 
sexes, whereas the prevalence rates increased up to 
65–69 years for males and 75–79 years for females, 
decreased until 90–94 years for males before increasing 
again, and decreased through the oldest age groups for 
females (igure 6C).
Age patterns across regions are provided in the 
appendix (pp 241–61). In high-income North America 
in 2017, the number of deaths was highest in the age 
groups from 50 to 69 years for both sexes combined, 
with an increasing trend in both the number and rate of 
deaths in these age groups from 1990 to 2017. In both 
1990 and 2017, death rates increased with age, up to and 
including the 95 years and older age group. The number 
of cirrhosis deaths in 2017 was also highest in the 
middle-aged age groups (50–74 years) in all other 
regions except Oceania (highest in the 40–55 year age 
groups) and high-income Asia Paciic (highest in the 
75–84 year age groups). However, unlike high-income 
North America, these regions, with the exception of 
eastern Europe, all experienced a decreasing trend in 
death rates in the middle-aged age groups over the 
study period.
The age patterns in central and eastern Europe were 
markedly diferent from other regions. Although the 
number of deaths in these regions peaked at 55–69 years 
in 2017, similar to other regions, death rates did not 
consistently increase with age. In 2017, death rates in 
central Europe declined from 70–74 years to 90–94 years, 
and in eastern Europe from 65–69 years to 80–84 years 
and increased again in the oldest age groups in both 
regions. In all other regions, death rates increased with 
increasing in age in all years from 1990 to 2017.
Between 1990 and 2017, the age-standardised death rate 
decreased or remained steady in all regions except central 
Asia and eastern Europe (igure 7A). In these two regions, 
the observed age-standardised death rates not only 
increased over the study period, but increased to much 
higher rates than those that would be expected based 
solely on SDI. The observed trend in these two regions 
was an increase in age-standardised death rate from 
1990 to the late 2000s, then a slight decrease until 2017. 
Overall, the age-standardised death rate was lower at the 
regional level at higher SDI levels, with expected rates 
following a roughly linear decreasing trend until SDI 
equalled 0·70, an increase in age-standardised death rate 
until an SDI of 0·75, then a decline through the highest 
SDI levels. High and increasing rates in eastern Europe 
explain the rise in expected rates at 0·70 SDI. At the 
national level, age-standardised death rates were also 
lower at higher SDI levels in 2017 (appendix p 262).
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(Figure 7 continues on next page)
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Figure 7: Age-standardised rates of cirrhosis globally and for 21 regions by SDI, 1990–2017
(A) Age-standardised death rate per 100 000 population. (B) Age-standardised DALY rate per 100 0000 population. (C) Age-standardised prevalence per 100 000 population of decompensated 
cirrhosis. (D) Age-standardised prevalence per 100 000 population of compensated cirrhosis. For each region, points from left to right depict estimates from each year from 1990 to 2017. Black lines 
show the expected death, DALY, or prevalence rates on the basis of SDI alone. DALYs=disability-adjusted life-years. SDI=Socio-demographic Index.
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The patterns of age-standardised DALY rates versus 
SDI were similar to those of age-standardised death rates 
(igure 7B; appendix p 262). In most regions, the observed 
age-standardised death and DALY rates were close to 
their expected value on the basis of SDI. The exceptions 
were western sub-Saharan Africa, southeast Asia, central 
Asia, and central Latin America, where observed levels 
were higher than expected in every year of the study 
period.
Age-standardised prevalence of decompensated 
cirrhosis was slightly higher at higher SDI levels, although 
it decreased at an SDI of 0·45 (because of low age-
standardised prevalence in Oceania and south Asia) and 
peaked at an SDI of 0·75 (because of high age-standardised 
prevalence in central and eastern Europe; igure 7C). 
Southern sub-Saharan Africa was the only region where 
age-standardised prevalence of decom pensated cirrhosis 
decreased over time. The pattern of compensated cirrhosis 
versus SDI was similar to that of decompensated cirrhosis, 
although most regions showed little change in rate over 
time. The high-income Asia Paciic region showed a 
decline in age-standardised prevalence of compensated 
cirrhosis over the study period, but it was still much 
higher than expected based on SDI (igure 7D).
Discussion
In this paper, we described the results of GBD 2017 
regarding cirrhosis mortality and morbidity by the 
four most common causes, and a ifth category of other 
causes. Of note, the four major causes of cirrhosis 
mortality and morbidity can generally be prevented by 
vaccination or lifestyle modiication and are readily 
treatable if diagnosed early enough.7 It is essential for 
national health-care policy makers to know the death and 
prevalence rates of each cause to be able to plan and 
implement systematic interventions that prevent 
premature deaths and morbidity due to cirrhosis.
The age-standardised death, DALY, and prevalence 
rates were universally lower in females than in males in 
both 1990 and 2017. Generally, females had a lower 
proportion of cirrhosis deaths caused by hepatitis B and 
alcohol-related liver disease than males, and had a higher 
proportion due to NASH and other causes. This trend 
could be driven by hormonal factors; lower prevalence of 
high-risk behaviours; higher prevalence of obesity;27 
lower consumption of alcohol;28 and diseases that almost 
exclusively afect women, such as autoimmune hepatitis, 
which has a simple and efective treatment and low 
mortality if treated in time.29
Our results show that in almost all regions, the number 
of deaths peaked in the middle-aged age groups 
(approximately 50–74 years) and rates increased steadily 
with increasing age. Central and eastern Europe were 
exceptions to these trends, and showed lower death rates 
in the older age groups (approximately 70–84 years) than 
in the middle-aged age groups throughout the study 
period. These indings suggest that cirrhosis incidence 
in these regions, where cirrhosis deaths are primarily 
driven by alcohol-related liver disease, was higher in the 
1990s, coinciding with peak consumption of alcohol 
following the dissolution of the Soviet Union, than in 
2017.28,30 Among high-income regions, high-income North 
America showed an unusual age pattern, with an 
increase in death rates in the 50–69 year age group from 
1990 to 2017. This inding is compatible with previous 
reports for the USA and Canada.31,32
Our results show that the numbers of deaths and 
DALYs due to cirrhosis increased globally between 
1990 and 2017. The increase in numbers was primarily 
driven by population growth and ageing across the globe, 
speciically in low-income and middle-income countries.26 
By contrast, age-standardised death and DALY rates 
decreased, and were lower at higher SDI levels. 
Accordingly, we observed high age-standardised death 
rates in low-income sub-Saharan African regions in 2017, 
despite a substantial decline since 1990, which is 
compatible with previous reports.33 However, we observed 
lower death rates in higher SDI countries and territories 
(eg, the lowest rate was in Singapore). These indings are 
expected because most cirrhosis-related deaths can be 
avoided in high-income countries through better access 
to health care and stronger health infrastructure. Notable 
exceptions are countries located in eastern Europe and 
central Asia, where, unlike in other regions, the age-
standardised death rates increased from 1990 to 2017, 
primarily driven by alcohol-related liver disease, which 
has also been reported previously.34 Similarly, in Latin 
American regions, a high proportion of deaths were due 
to alcohol-related liver disease, although age-standardised 
death rates were not as high as those in eastern Europe 
and central Asia. These patterns closely follow the 
distribution of alcohol consumption in these regions.28,30
In western Europe, despite low age-standardised death 
rates, a high proportion of deaths were due to alcohol-
related liver disease. This inding is consistent with 
previous evidence on high alcohol use in these 
regions28,30,34 and demonstrates a need for a systematic 
approach to reducing alcohol use in these countries. To 
this end, in 2010, the member states of WHO reached a 
consensus at the World Health Assembly on a global 
strategy to confront the harmful use of alcohol.35
High-income regions had low age-standardised rates of 
cirrhosis deaths. Most of these regions, including 
Australasia, high-income North America, and western 
Europe, also had low age-standardised prevalences of 
both compensated and decompensated cirrhosis as a 
result of concerted eforts to treat and prevent viral 
hepatitis.34,36 The estimated age-standardised prevalence 
and death rates caused by cirrhosis in this study were 
slightly higher but generally compatible with previous 
reports from the USA and released by the US Centers for 
Disease Control and Prevention.37 The estimated age-
standardised death rates in the UK were also consistent 
with previous reports.38
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The high-income Asia Paciic countries, especially 
Japan and South Korea, had a high but declining age-
standardised prevalence rate of compensated cirrhosis, 
despite having low mortality rates.39 Prevalence trends 
could indicate a high incidence in preceding decades 
followed by a recent decline in mortality because of 
improved health care and access to afordable and 
efective antiviral treatment. Accordingly, in 2005, the 
WHO Western Paciic region set a goal to reduce HBsAg 
seroprevalence in children 5 years of age and older to less 
than 2% by 2012. A supranational goal was selected to 
create a sense of political urgency to establish routine 
immunisation and improve access to health care.39 A 
similar approach might be successful in African and 
other Asian countries, as well as in the region of north 
Africa and the Middle East, to control the incidence of 
hepatitis B; cirrhosis deaths in these regions were mainly 
due to hepatitis B and C.
Southeast Asia had higher age-standardised death 
rates than expected, and south Asia and Oceania had 
modest death rates, but these three regions were among 
those with the lowest age-standardised prevalence of 
com pensated and decompensated cirrhosis. Mortality 
was primarily due to hepatitis B in these regions. The 
low age-standardised prevalence of compensated 
cirrhosis in these regions might be because of a low 
detection rate, whereas the low age-standardised 
prevalence of decom pensated cirrhosis might be 
because of a relatively poor medical infrastructure, 
leading to a short survival time once the cirrhosis starts 
to decompensate.40
In north Africa and the Middle East, alcohol-related liver 
disease constituted the lowest proportion of age-
standardised prevalence and death rates.19 This inding 
could be expected, because alcohol is prohibited in many of 
the countries in this region, which could lead to both 
decreased use and the possibility of under-reporting. 
Instead, hepatitis B and C constitute larger proportions. 
Despite a decrease in age-standardised death rates in this 
region, hepatitis B is still the major cause of cirrhosis 
deaths, and although most countries in these regions have 
nationwide infant vaccination programmes for hepatitis B, 
none have been in place for more than 30 years.41 Most of 
the mortality of hepatitis B is in patients older than 40 years, 
so we expect hepatitis B to remain a major cause of cirrhosis 
death for another decade or two, even in countries with 
good vaccine coverage.
Hepatitis C, by contrast, now has an efective cure, 
which should have an impact much sooner. With the 
increased availability of cheap generic anti-hepatitis C 
virus medicines,42 we expect the death rate for hepatitis C 
to rapidly decrease in the near future, if countries are able 
to meet the goals set by WHO to eliminate the burden of 
hepatitis C by 2030.43 For example, in Egypt, which 
currently has the highest death rate due to hepatitis C,19 we 
expect a rapid decrease in the hepatitis C death rate within 
the next 5–10 years because of an active patient-inding 
and treatment programme enacted by the government in 
2014.44 Australia has also been successful in inding and 
treating patients with hepatitis C and will probably have 
very low hepatitis C death rates in the near future.45
Between 1990 and 2017, we observed a doubling in the 
number of deaths, a more than tripling in prevalent cases 
of decompensated cirrhosis, and a more than doubling 
in prevalent cases of compensated cirrhosis due to 
NASH. Unlike the other four causes studied, NASH was 
the only one not to show a decreasing trend in age-
standardised death rates. The highest proportions of 
deaths due to NASH were in Latin America and north 
Africa and the Middle East, and the lowest was in high-
income Asia Paciic, as previously reported.46 The 
epidemiology of NASH closely follows the distribution of 
overweight and obesity and components of metabolic 
syndrome in these regions.27,47 Because of the absence of 
practical means of preventing or treating NASH and a 
global increase in metabolic syndrome and obesity, we 
should expect an increase in the burden of this disease.16,17
Despite the availability of an efective vaccine for 
hepatitis B for decades, the availability of an efective 
treatment for hepatitis C, and an increase in obesity 
worldwide, the proportional contribution of diferent 
causes to cirrhosis remained fairly constant between 
1990 and 2017 at the global level. The development of 
cirrhosis and its progression to decompensation takes 
decades, and it might still be too early to see the efects of 
vaccination coverage or increased prevalence of obesity 
and metabolic syndrome.
The limitations of the methods of GBD impose biases 
on our estimates in the current study, as with all GBD 
research. The most important limitation is the low 
availability and low quality of data, although we used 
robust statistical methods to overcome data scarcity in 
countries with low data availability. In these locations, we 
relied on predictive covariates, trends in neighbouring 
countries, or a combination of these. The wide variation 
in the availability of high-quality data across locations is 
relected in the uncertainty associated with all estimates. 
As a result of lower availability of population-based data 
on the prevalence of cirrhosis, dependence on hospital 
and claims data, and various deinitions and diagnostic 
criteria for decompensated and compensated cirrhosis, it 
is possible that both types, especially compensated 
cirrhosis, have been underestimated. We made the 
assumption that patients admitted to hospitals had 
decompensated cirrhosis and that total cases detected 
upon admission constituted all cases of cirrhosis. Of 
note, although ICD-10 codes have been validated for 
overall cirrhosis and chronic liver diseases, detailed codes 
for the ive causes have not been fully validated. To 
address this challenge, we combined the aetiological 
models for cirrhosis and liver cancer, as these two diseases 
share the same causes. Aetiological proportion models of 
liver cancer were used as covariates for cirrhosis 
aetiological proportion models. Finally, advances in 
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imaging modalities and the availability of liver biopsy as 
the gold standard for detecting cirrhosis in population-
based studies can considerably improve the accuracy of 
estimations.
Further work is needed to disentangle the separate 
entities that were categorised as other causes in this 
study, including autoimmune hepatitis as a sixth cause 
for cirrhosis. A detailed study on the epidemiology of 
NASH, particularly in north Africa and the Middle East 
and Latin America, is needed because it disproportionately 
afects age-standardised death rate as compared with 
other causes. Future studies should focus on evaluating 
common risk factors, dietary patterns, and screening 
practices afecting the incidence, mortality, and 
prevalence of cirrhosis by age, sex, and race, especially 
among countries and territories with the highest 
numbers of deaths. The inancial burden of cirrhosis 
also merits attention in future studies.
In conclusion, the major causes of cirrhosis are 
preventable and treatable; however, setting cost-efective 
policies to prevent and treat cirrhosis requires high-
quality, localised data. GBD provides the most up-to-date 
estimates on the burden of cirrhosis by cause to guide 
policy makers in designing efective preventive plans and 
implementing interventions at national and even 
subnational levels. In line with the Global Health Sector 
Strategy on Viral Hepatitis 2016 to 2021, the Sustainable 
Development Goals, and the WHO Global Strategy to 
Reduce Harmful Use of Alcohol, there is a need to 
implement compre hensive prevention eforts to achieve 
a sustained reduction in cirrhosis burden.
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